Review of cholesterol-lowering therapy: Coronary angiographic and events trials

American Journal of Medicine

Volumn 101, Issue 4 A, 1996, Pages 34S-39S

  Waters, David ^a   Pedersen, Terje R ^b  

^a HARTFORD HOSPITAL   (United States)

^b AKER UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; SIMVASTATIN; HYPOCHOLESTEROLEMIC AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ANGIOCARDIOGRAPHY; ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONFERENCE PAPER; HUMAN; HYPERCHOLESTEROLEMIA; META ANALYSIS; MORTALITY; PRIORITY JOURNAL; REVASCULARIZATION; SUDDEN DEATH; BLOOD; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; DISEASE COURSE; REVIEW; SURVIVAL RATE;

ANTICHOLESTEREMIC AGENTS; CHOLESTEROL, LDL; CLINICAL TRIALS; CORONARY ANGIOGRAPHY; CORONARY ARTERIOSCLEROSIS; CORONARY DISEASE; DISEASE PROGRESSION; HUMANS; HYPERCHOLESTEROLEMIA; SURVIVAL RATE;

EID: 0029661988     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9343(96)00318-X     Document Type: Conference Paper

References (37)

1. Brensike JF, Levy RI, Kelsey SF, et al. Effects of therapy and cholestyramine on progression of coronary atherosclerosis. Results of the NHLBI Type II Coronary Intervention Study. Circulation. 1984;69:313-324.
2. Blankenhorn DH, Nessim SA, Johnson RL, et al. Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. JAMA. 1987;257:3233-3240.
3. Buchwald H, Varco RL, Matts JP, et al. Effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia. N Engl J Med. 1990;323:946-955.
4. Brown G, Albers JJ, Fisher LD, et al. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med. 1990;323:1289-1298.
5. Kane JP, Malloy MJ, Ports TA, et al. Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimens. JAMA. 1990;264:3007-3012.
6. Schuler G, Hambrecht R, Schlierf G, et al. Regular physical exercise and low fat diet - effect on progression of coronary artery disease. Circulation. 1992;86:1-11.
7. Watts GF, Lewis B, Brunt JNH, et al. Effects on coronary artery disease of lipid-lowering diet, or diet plus 12 cholestyramine, in the St. Thomas' Atherosclerosis Regression Study (STARS). Lancet. 1992;339:565-569.
8. Blankenhorn DH, Azen SP, Kramsch DM, et al. Coronary angiographic changes with lovastatin therapy: the Monitored Atherosclerosis Regression Study (MARS). Ann Intern Med. 1993;119:969-976.
9. Waters D, Higginson L, Gladstone P, et al. Effects of monotherapy with an HMG CoA reductase inhibitor upon the progression of coronary atherosclerosis as assessed by serial quantitative arteriography: the Canadian Coronary Atherosclerosis Intervention Trial (CCAIT). Circulation. 1994;89:959-968.
10. Haskell WL, Alderman EL, Fair JM, et al. Effects of intensive multiple risk factor reduction on coronary atherosclerosis and clinical cardiac events in men and women with coronary artery disease: the Stanford Coronary Risk Intervention Project (SCRIP). Circulation. 1994;89:975-990.
11. Sacks FM, Pasternak RC, Gibson CM, et al. Effect on coronary atherosclerosis of decrease in plasma cholesterol concentrations in normocholesterolaemic patients. Lancet. 1994;344:1182-1186.
12. MAAS Investigators. Effect of simvastatin on coronary atheroma: the Multicentre Anti-Atheroma Study (MAAS). Lancet. 1994;344:633-638.
13. Pitt B, Mancini GBJ, Ellis SG, et al. Pravastatin Limitation of Atherosclerosis in the Coronary Arteries (PLAC-1): reduction in atherosclerosis progression and clinical events. J Am Coll Cardiol. 1995;26:1133-1139.
14. Ornish D, Brown SE, Scherwitz LW, et al. Can lifestyle changes reverse coronary heart disease? Lancet. 1990;336:129-133.
15. Wouter JuKema J, Bruschke AVG, van Boven AJ, et al. Effects of lipid-lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The Regression Growth Evaluation Statin Study (REGRESS). Circulation. 1995;91:2528-2540.
16. Waters D. Lessons from coronary atherosclerosis "regression" trials. Cardiology Clin. 1996;14:31-50.
17. Little WC, Constantinescu M, Applegate RJ, et al. Can coronary angiography predict the site of a subsequent myocardial infarction in patients with mild-to-moderate coronary artery disease? Circulation. 1988;78:1157-1166.
18. Taeymans Y, Théroux P, Lespérance J, Waters D. Quantitative angiographic morphology of the coronary artery lesions at risk of thrombotic occlusion. Circulation. 1992;85:78-85.
19. Hunninghake DB, Campeau L, for the Post-Coronary Artery Bypass Graft (CABG) Investigators. Post-coronary artery bypass graft trial: primary results of intensive LDL-cholesterol lowering and low dose anticoagulation in delaying obstructive changes in coronary bypass grafts. Presented at the 1996 Annual Meeting of the American College of Cardiology, March, Orlando, FL.
20. Waters D, Craven TE, Lespérance J. Prognostic significance of progression of coronary atherosclerosis. Circulation. 1993;87:1067-1075.
21. Buchwald H, Matts JP, Fitch LL, et al. Changes in sequential coronary arteriograms and subsequent coronary events. JAMA. 1992;268:1429-1433.
22. Buchwald H, Campos CT, Boen JR, et al. Disease-free intervals after partial ileal bypass in patients with coronary heart disease and hypercholesterolemia: report from the Program on the Surgical Control of the Hyperlipidemias (POSCH). J Am Coll Cardiol. 1995;26:351-357.
23. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383-1389.
24. Kjekshus J, Pedersen TR, for the Scandinavian Simvastatin Survival Study Group. Reducing the risk of coronary events: evidence from the Scandinavian Simvastatin Survival Study (4S). Am J Cardiol. 1995;76:64C-68C.
25. Scandinavian Simvastatin Survival Study Group. Baseline serum cholesterol and treatment effect in the Scandinavian Simvastatin Survival Study (4S). Lancet. 1995;345:1274-1275.
26. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med. 1996;335:1001.
27. Martin MJ, Hulley SB, Browner WS, Kuller LH, Wentworth D. Serum cholesterol, blood pressure, and mortality: implications from a cohort of 361,662 men. Lancet. 1986;ii:933-939.
28. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, Macfarlane PW, McKillop JH, Packard CJ for the West of Scotland Coronary Prevention Study Group. N Engl J Med. 1995;333:1301-1307.
29. Treasure CB, Klein JL, Weintraub WS, et al. Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. N Engl J Med. 1995;332:181-187.
30. Law MR, Wald NJ, Thompson SG. By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischemic heart disease? Br Med J. 1994;308:367-373.
31. Gould AL, Rossouw JE, Santanello NC, Heyse JF, Furberg CD. Cholesterol reduction yields clinical benefit. A new look at old data. Circulation. 1995;91:2274-2282.
32. Holme I. Cholesterol reduction and its impact on coronary artery disease and total mortality. Am J Cardiol. 1995;76(suppl):10C-17C.
33. Pedersen TR, Olsson AG, Færgeman O, Berg K, Mieitinen T, Wedel H, for the 4S Group. Simvastatin-induced reduction of major coronary events is related to both reduction in LDL-cholesterol and increase in HDL-cholesterol. (Abstr.) Circulation. 1995;92:1-198.
34. Thompson GR, Hollyer J, Waters DD. Percentage change rather than plasma level of LDL-cholesterol determines therapeutic response in coronary heart disease. Curr Opinion Lipidology. 1995;6:386-388.
35. Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults: summary of the second report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults. JAMA. 1993;269:3015-3023.
36. Chen Z, Peto R, Collins R, MacMahon S, Lu J, Li W. Serum cholesterol concentration and coronary heart disease in populations with low cholesterol concentrations. Br Med J. 1991;303;276-282.
37. Kjekshus J, Pedersen TR, Tobert JA. Lipid-lowering therapy for patients with or at risk of coronary artery disease. Curr Opin Cardiol. 1996;11:418-427.